276 related articles for article (PubMed ID: 35558005)
21. Current and emerging therapies for primary central nervous system lymphoma.
Yuan Y; Ding T; Wang S; Chen H; Mao Y; Chen T
Biomark Res; 2021 May; 9(1):32. PubMed ID: 33957995
[TBL] [Abstract][Full Text] [Related]
22. Primary central nervous system lymphoma.
Löw S; Han CH; Batchelor TT
Ther Adv Neurol Disord; 2018; 11():1756286418793562. PubMed ID: 30305848
[TBL] [Abstract][Full Text] [Related]
23. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
24. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
Tateishi K; Miyake Y; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of primary central nervous system lymphoma.
Han CH; Batchelor TT
Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
Liu Y; Yao Q; Zhang F
Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
[TBL] [Abstract][Full Text] [Related]
27. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.
Zhang X; Liu Y
CNS Neurol Disord Drug Targets; 2020; 19(3):165-173. PubMed ID: 32416683
[TBL] [Abstract][Full Text] [Related]
29. Central Nervous System Lymphomas.
Grommes C
Continuum (Minneap Minn); 2020 Dec; 26(6):1476-1494. PubMed ID: 33273169
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival in AIDS-related primary central nervous system lymphoma.
Gupta NK; Nolan A; Omuro A; Reid EG; Wang CC; Mannis G; Jaglal M; Chavez JC; Rubinstein PG; Griffin A; Abrams DI; Hwang J; Kaplan LD; Luce JA; Volberding P; Treseler PA; Rubenstein JL
Neuro Oncol; 2017 Jan; 19(1):99-108. PubMed ID: 27576871
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment.
Zhou L; Li Q; Xu J; Wang S; Song Z; Chen X; Ma Y; Lin Z; Chen B; Huang H
Neurooncol Adv; 2023; 5(1):vdac181. PubMed ID: 36879663
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
35. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.
Ambady P; Doolittle ND; Fox CP
Ann Lymphoma; 2021 Sep; 5():23. PubMed ID: 35253010
[TBL] [Abstract][Full Text] [Related]
36. CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
Karschnia P; Blobner J; Teske N; Schöberl F; Fitzinger E; Dreyling M; Tonn JC; Thon N; Subklewe M; von Baumgarten L
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065471
[TBL] [Abstract][Full Text] [Related]
37. The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma.
Zhou X; Mulazzani M; von Mücke-Heim IA; Langer S; Zhang W; Ishikawa-Ankerhold H; Dreyling M; Straube A; von Baumgarten L
Front Oncol; 2020; 10():682. PubMed ID: 32528875
[TBL] [Abstract][Full Text] [Related]
38. Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.
Zhou Y; Xu X
Hematology; 2022 Dec; 27(1):105-112. PubMed ID: 35068379
[TBL] [Abstract][Full Text] [Related]
39. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
40. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]